Janux Therapeutics JANX Current ratio
Current ratio at other companies
Other financials
Where this comes from
Calculated from Janux Therapeutics’s reported figures.
Based on the most recent quarter.
The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Janux Therapeutics's current ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Janux Therapeutics's current ratio?
- Janux Therapeutics (JANX) reported current ratio of 17× in Q1 2026.
- How has Janux Therapeutics's current ratio changed year-over-year?
- Janux Therapeutics's current ratio decreased by 70.9% year-over-year, from 58.5× to 17×.
- What is the long-term trend for Janux Therapeutics's current ratio?
- Over 5 years (2020 to 2025), Janux Therapeutics's current ratio has grown at a 50.5% compound annual growth rate (CAGR), from 5× to 39×.
- What does current ratio mean?
- Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.